新鮮ステージD2前立腺癌に対する化学内分泌療法

Abstract

ステージD2前立腺癌新鮮例175例を対象に, 化学療法併用内分泌療法群38例(化療あり群), 内分泌療法単独群137例(化療なし群)に分け, その治療成績を比較検討した.尚, 化療あり群のレジメンは, VIPが34例, CDDP+IFMが2例, CBDCA+VPが1例, CDDP+MTXが1例であった.その結果, 1)全症例の5年生存率は34.8%, 疾患特異的5年生存率は41.7%で, うち化療なし群の疾患特異的5年生存率は34.8%であったのに対し, 化療あり群は61.6%と有意に良好であった.2)Coxの比例ハザードモデルを用いた多変量解析においては, 最も強い相関がみられたのは全生存においては治療開始年代であったが, 疾患特異的生存においては化学療法の有無が最も強い相関を示した

We evaluated 175 patients with newly diagnosed stage D2 prostate cancer who had been treated in our hospital between 1992 and 2003 to compare chemo-endocrine therapy with endocrine therapy alone. One hundred and thirty seven patients were treated with endocrine therapy alone. The other 38 patients received chemo-endocrine therapy, which included medical or surgical castration with/without antiandrogen plus VIP (Vincristine, Ifosfamide, Peplomycin) regimen or other cytotoxic agents. The patients treated with chemo-endocrine therapy had a significantly better prognosis than the patients treated with endocrine therapy alone (p<0.05), although treatment was not randomized. The cause-specific survival rates at 5 years for the chemo-endocrine therapy group and the endocrine therapy group were 61.6% and 34.8%, respectively. These data suggest that chemo-endocrine therapy is a potentially effective treatment for newly diagnosed stage D2 prostate cancer.